Navigation Links
Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
Date:5/16/2012

LONDON, ON A scientist at Lawson Health Research Institute has been honored in Pfizer Canada's first-ever Psychiatry Research Awards Program. Dr. Elizabeth Osuch, Scientist and Rea Research Chair of Affective and Anxiety Disorders at Lawson, is one of two researchers to receive $100,000 to support their research.

Dr. Osuch's winning proposal aims to improve diagnosis of bipolar disorder in youth. In young people, the depressive symptoms associated with bipolar disorder are often misdiagnosed as "unipolar" major depressive disorder. The average misdiagnosis often lasts 6-10 years. In the meantime, if the patient is treated with antidepressants, their condition declines.

Through the Psychiatry Research Awards Program, Dr. Osuch will use functional brain imaging in an effort to distinguish patients with bipolar disorder from those with unipolar depression. By observing different networks within the brain, she hopes to improve diagnostic accuracy and patient quality of life.

"I am very pleased to have been recognized by Pfizer for my research, which I truly do believe will have an impact on Canadians living with mental illness," Dr. Osuch says. "This award will help further my research efforts and advance the translation of medical research into patient care."

The Psychiatry Research Awards Program is a competitive research grant program open to all researchers interested in psychiatric diseases including physicians and academics. It was launched in May 2011 to advance clinical research and patient care in psychiatry by supporting Canadian investigators in their research efforts.


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Lawson researchers engineer a switch to tame aggressive cancers
2. Lawson proves real people drive research
3. Lawson scientist presents joint pain treatment 2.0
4. Breast cancer effectively treated with chemical found in celery, parsley by MU researchers
5. New biomarker test predicts arthritis at much earlier stage, MU researchers say
6. Boston researcher, surgical oncologist receives national award
7. Researchers Test Laxative-Free Colon Scan
8. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
9. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
10. Researchers see BPA effects in monkey mammary glands
11. A place to play: Researcher designs schoolyard for children with autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology: